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Abstract
Rationale A dimensional approach in psychiatry aims to iden-
tify core mechanisms of mental disorders across nosological
boundaries.
Objectives We compared anticipation of reward between ma-
jor psychiatric disorders, and investigated whether reward
anticipation is impaired in several mental disorders and
whether there is a common psychopathological correlate (neg-
ative mood) of such an impairment.
Methods We used functional magnetic resonance imaging
(fMRI) and a monetary incentive delay (MID) task to study
the functional correlates of reward anticipation across major
psychiatric disorders in 184 subjects, with the diagnoses of
alcohol dependence (n=26), schizophrenia (n=44), major
depressive disorder (MDD, n=24), bipolar disorder (acute
manic episode, n=13), attention deficit/hyperactivity disorder
(ADHD, n=23), and healthy controls (n=54). Subjects’ indi-
vidual Beck Depression Inventory-and State-Trait Anxiety
Inventory-scores were correlated with clusters showing sig-
nificant activation during reward anticipation.
Results During reward anticipation, we observed significant
group differences in ventral striatal (VS) activation: patients
with schizophrenia, alcohol dependence, and major depres-
sion showed significantly less ventral striatal activation com-
pared to healthy controls. Depressive symptoms correlated
with dysfunction in reward anticipation regardless of diagnos-
tic entity. There was no significant correlation between anxi-
ety symptoms and VS functional activation.
Conclusion Our findings demonstrate a neurobiological dys-
function related to reward prediction that transcended disorder
categories and was related to measures of depressed mood.
The findings underline the potential of a dimensional ap-
proach in psychiatry and strengthen the hypothesis that neu-
robiological research in psychiatric disorders can be targeted
at core mechanisms that are likely to be implicated in a range
of clinical entities.
Keywords Dimensional . fMRI . Reward system . Ventral
striatum .Monetary incentive delay task . Depressive
symptoms
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Introduction
To date, neurobiological research has identified a variety of
dysfunctions implicated in psychiatric disorders, e.g., anhedo-
nia or disturbances in cognition and memory; however, these
do not necessarily provide a neurobiological validation of
existing disorder categories (Heinz 2002; Robbins et al.
2012; van Os and Kapur 2009). Clinical categories such as
“schizophrenia” or “major depressive disorder” (MDD) are
complex phenotypes composed of patterns of symptoms with
diverse neurobiological signatures (van Os and Kapur 2009).
It has been suggested for some time that psychiatric disorders
should be separated into their components for diagnostic and
treatment purposes, as it is often done in somatic disorders
(Heinz 2002; Van Praag et al. 1990). Such a dimensional
approach tries to identify neurobiological correlates of core
psychological mechanisms, which are often observed in dif-
ferent combinations and various severities in psychiatric dis-
orders (Insel et al. 2010). We and others have suggested that a
dimensional approach can be applied across nosological
boundaries in major psychiatric disorders and used to identify
neurobiological signatures of core (dys)functions, such as
positive and negative moods as well as learning from reward
and punishment (Insel et al. 2010; Watson and Clark 1988).
This approach can be promising for the understanding of
psychiatric symptoms and for the development of new treat-
ment strategies (Canli and Lesch 2007; Insel 2012; Robbins
et al. 2012). For example, several studies focused on seroto-
nergic (dys)function in healthy participants and across psychi-
atric disorders, as well as on neurobiological correlates of
(an)hedonia in schizophrenia, depression, and alcohol depen-
dence (Canli et al. 2002; Hariri et al. 2002; Heinz et al. 1994,
2005a). With respect to dopaminergic neurotransmission, it
was originally hypothesized that dopamine release is associ-
ated with the rewarding (pleasurable and hence hedonic)
effects of the drug or action that caused dopamine stimulation
(Wise 1988). However, based on primate and rodent studies, it
was suggested that phasic dopamine release mediates the
motivational state of wanting rather than the hedonic pleasure
of enjoying a reward (Robinson and Berridge 1993). We and
others observed that dopamine release was associated both
with positive mood and with craving for reward, while dopa-
mine dysfunction was associated with motivational impair-
ment (apathy) more strongly than with the inability to enjoy
pleasure (anhedonia) (Drevets et al. 2001; Heinz et al. 1998;
Schmidt et al. 2001).
Animal experiments point to the ventral striatum (VS) as a
key area coding reward anticipation and feedback. Functional
paradigms to study reward anticipation and learning from
reinforcement have been developed on the basis of a compu-
tational account of dopamine discharge patterns elicited by
violations of expectations, e.g., by unexpected cues predicting
reward and by prediction errors due to unexpected reward
feedback (Knutson et al. 2001b; Montague et al. 2004;
Schultz 1998). Studies in nonhuman primates have indicated
that unexpected reward or the appearance of a reward-
predicting cue lead to phasic activation of dopaminergic pro-
jections including those to the ventral striatum (Schultz et al.
1997). These findings have been translated into an fMRI
paradigm, the so-called “Monetary Incentive Delay (MID)
task” by Knutson et al. (2000). An increase in firing of
dopaminergic neurons is thought to change activation of the
ventral striatum and thus affect the blood oxygen level-
dependent (BOLD) signal measured via fMRI. In fact, the
MID task is known to robustly activate the VS during reward
anticipation and to a lesser degree also during anticipation of
loss (Knutson et al. 2001a, b), and this has been shown to
significantly correlate with key dopamine indicators such as
release and synthesis capacity (Schlagenhauf et al. 2013;
Schott et al. 2008).
Applying the MID task to a variety of psychiatric disorders
was inspired by the idea that dopaminergic dysfunction can
affect motivation and mood in several disorders such as major
depression, schizophrenia, and alcohol dependence (Bjork
et al. 2012; Hasler et al. 2009; Knutson et al. 2008; Nielsen
et al. 2012; Simon et al. 2010) (see supplement Table 1). Our
own group observed blunted ventral striatal activation elicited
by reward-predicting cues in these diagnostic groups com-
pared to healthy controls, and mixed results or no significant
group differences in patients with mania or attention deficit/
hyperactivity disorder compared to healthy controls (Beck
et al. 2009; Bermpohl et al. 2010; Juckel et al. 2006a, b;
Schlagenhauf et al. 2008, 2009; Stoy et al. 2012; Strohle
et al. 2008; Wrase et al. 2007). These observations suggest
that blunted ventral striatal activation during reward anticipa-
tion may figure prominently in disorders associated with
negative mood states such as schizophrenia, alcohol depen-
dence, and depression, but may not be present in disorders
characterized by elevated mood such as mania. The recently
revived interest in the dimensional approach (Insel et al. 2010)
as well as a study of reward anticipation in adolescents (Bebko
et al. 2014) encouraged us to compare dysfunction of the
reward system across different psychiatric disorders by
pooling our data and enlarging our sample with further sub-
jects. Data (n=184) were available in five different psychiatric
disorders (alcohol dependence, schizophrenia, major depres-
sive disorder, acute manic episode of bipolar disorder, and
attention deficit/hyperactivity disorder (ADHD)), as well as
healthy controls. All subjects underwent scanning with the
same MRI scanner using the same protocol and the same
scores to assess negative mood (i.e., the Beck Depression
Inventory (BDI (Beck et al. 1997)) and the State-Trait Anxiety
Inventory (STAI (Spielberger et al. 1970)). According to the
literature mentioned above, we hypothesized to observe re-
duced ventral striatal activation in patients with schizophrenia,
alcohol dependence, and major depression (but not with acute
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manic episode or ADHD) during reward anticipation. We also
explored whether negative mood states such as anxiety or
depression correlated with impaired VS activation during
reward anticipation across diagnostic groups.
Methods
Subjects
One hundred thirty-three patients and 54 healthy volunteers
participated in this study. Patients were recruited from the
inpatient and outpatient center of the Department of Psychia-
try and Psychotherapy, Charité-Universitätsmedizin Berlin,
Campus Charité Mitte. Healthy controls were recruited from
the local community by advertisement. Ethical approval was
provided by the local ethics committee, and written informed
consent was obtained from all participants after complete
description of the study.
All participants were right-handed, as assessed with the
Edinburgh Handedness Inventory (Oldfield 1971). Exclusion
criteria were current neurological or severe medical disorders,
history of head injury resulting in loss of consciousness, and
age below 18 or above 65 years. Healthy volunteers had no
personal or family history of any psychiatric axis I or II
disorder as assessed with the Structured Clinical Interview
for DSM-IV disorders (SCID I/II; (First et al. 1997, 2001))
and were not under psychotropic medication.
Patients were diagnosed according to ICD-10 and DSM-IV
(assessed with the SCID I and II). Only patients with a single
axis I disorder from the following five disorder groups were
included: alcohol dependence (ICD-10: F10.2), schizophrenia
(ICD-10: F20.0), major depressive disorder (ICD-10: F32.1,
F32.2, F33.1, F33.2), bipolar disorder with acute manic epi-
sode (ICD-10: F31.1), and attention deficit/hyperactivity dis-
order (ADHD; ICD-10: F90.0), respectively. All patients were
without a personal history of comorbid psychiatric disorders
(SCID I/II), except for nicotine dependence. Disorder-specific
comparisons between subgroups of patients and healthy con-
trols (altogether n=95) have previously been published (Beck
et al. 2009; Bermpohl et al. 2010; Juckel et al. 2006a, 2012;
Schlagenhauf et al. 2008, 2009; Schmack et al. 2008; Stoy
et al. 2011, 2012; Strohle et al. 2008; Wrase et al. 2007). Here,
we report an increased sample of 133 patients and 54 controls.
For a detailed description of the sample as well as specific,
disease-related scores, please see Tables 1 and 2. Three sub-
jects (one patient with alcohol dependence, two with schizo-
phrenia) were identified as outliers with regard to the mean
effect size in the VS region of interest (ROI) for the main
contrast “anticipation of gain minus neutral cues” with a z
value of >3 and therefore excluded. The final group consisted
of 54 healthy volunteers (13 women, mean±STD 37.7±
11.1 years) and 130 patients (32 women, 36.7±10.4 years)
(see Table 1).
Ratings of subjective depressive symptoms with the BDI
(Beck et al. 1997) and ratings of subjective anxiety symptoms
with the STAI (Spielberger et al. 1970) were assessed across
diagnostic groups. Altogether, in 83 patients (no patients with
acute manic episode included) and 49 controls, BDI ratings
were available, and STAI ratings were available in 61 patients
(no patients with schizophrenia included) and 43 controls. We
compared participants whose BDI was available with partic-
ipants whose BDI had not been assessed to rule out any
differences between them, using a MANOVA with “existing
BDI” coded as “0” and “missing BDI” coded as “1.” Like-
wise, we controlled for differences between participants with
and without STAI.
Monetary incentive delay task
A modified version of the MID task as described by Knutson
et al. (2001a, b) was used to study the BOLD response during
anticipation and feedback of monetary reward (gain) and
punishment (loss). The subjects’ monetary gain depended on
their performance in a simple reaction time task where they
had to respond while a target stimulus was presented (Fig. 1).
Each trial started with presentation of a cue indicating
whether subjects could win money (circle), avoid losing mon-
ey (square) or neither (neutral cue, triangle). The magnitude of
the incentive (0.10 €; 0.60 €, or 3 €) was denoted by the
number of horizontal lines (1, 2, or 3) inside the cue. Before
scanning, participants were taught about the meaning of the
seven different cues and that they would receive any earned
money after the scanning session was completed. A training
session without monetary reimbursement took place during
the acquisition of the anatomical scan. Between cues and
target, a variable delay (mean 3,990 ms) was inserted. After
responding, feedback was given for 1,650 ms. Due to appli-
cation of an adaptive algorithm for target duration, subjects
succeeded on about 67 % of the trials. Hits (=success) were
defined as button presses within the time frame of the target
presentation (maximum 1 s). Subjects performed two sessions
consisting of 54 gains, 54 losses, and 36 neutral trials, which
were presented in a random sequence. Each run lasted about
14 min with a mean trial duration of approximately 7.69 s and
a mean intertrial interval of 3.53 s.
MRI scanning
Event-related fMRI was performed on a 1.5-T scanner
(Magnetom VISION Siemens®) using gradient-echo echo-
planar imaging (GE-EPI, repetition time (TR)=1.9 s for the
MID task, echo time (TE)=40 ms, flip angle=90°, matrix=
64×64) with a voxel size of 4×4×3.3 mm3. Eighteen slices
were collected approximately parallel to the bicommissural
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plane (ac-pc plane). For anatomical reference, a 3D
magnetization-prepared rapid gradient echo (MPRAGE;
TR=9.7 ms; TE=4 ms; flip angle 12°, matrix=256×256,
voxel size 1×1×1 mm3) image data set was acquired.
Data processing and analysis
Functional MRI data were analyzed with the Statistical Para-
metric Mapping 8 (SPM8) software package (http//www.fil.
ion.ucl.ac.uk/spm) and the ArtRepair software developed by
Mazaika and colleagues (2005) (http://cibsr.stanford.edu/
tools/human-brain-project/artrepair-software.html). The
ventral striatal, insula, and amygdala ROIs were specified
from the publication-based probabilistic Montreal Neurologi-
cal Institute (MNI) atlas used as binary masks at the threshold
of 0.75 probability (please refer to http://hendrix.imm.dtu.dk/
services/jerne/ninf/voi/index-alphabetic.html).
First, we used ArtRepair to correct images for technical
artifacts. After discarding the first three volumes, we then
performed slice time correction, realignment, spatial normal-
ization into theMNI standard space, and smoothing with an 8-
mm full-width-at-half-maximum Gaussian kernel. Patients
and controls did not differ in their maximum, mean, and
cumulative head motion (repeated measures ANOVA with
time as intrasubject factor and group as between subject
factor: all main effects and interaction p>0.1). The
preprocessed fMRI data was analyzed using the general linear
model approach in a two-stage model. Due to significant
group differences in age, gender, and smoking behavior
(smokers/nonsmokers), those three variables were modeled
as covariates throughout all analyses.
On the individual first level, the seven cue conditions, the
target, and the five feedback conditions (successful gain,
nonsuccessful gain, successful loss avoidance, nonsuccessful
loss avoidance, neutral condition) were modeled separately as
regressors after being convolved with a canonical hemody-
namic response function (HRF). Realignment parameters
were included as additional regressors. For the anticipation
Table 2 Specific diagnosis-related scores
Diagnosis Psychopathological measurement scale Mean±standard
deviation
Alcohol dependence Alcohol Dependence Scale (Severity of Alcohol
Dependence (Skinner and Horn 1984))
20.7±6.7
Obsessive Compulsive Drinking Scale (Severity
of Alcohol Craving (Anton 2000))
20.9±6
Schizophrenia Positive and Negative Syndrome Scale (PANSS (Kay et al. 1987)) 85.7±27.2
Major depressive disorder (MDD) Hamilton rating Scale for Depression (HRSD-21 (Hamilton 1960)) 20.4±4.1
Bipolar disorder, acute manic episode Young Mania Rating Scale (YMRS (Young et al. 1978)) 19.6±6.4
Attention deficit/hyperactivity disorder (ADHD) Conner’s Adult ADHD Rating Scale (Conners et al. 1999) 64.1±14.4
Fig. 1 Experimental paradigm “monetary incentive delay task”. (a) Trial
structure for a representative successful gain (3 €) trial. (b) Theoretical
background: phasic dopamine outburst at the time of a reward-predicting
cue and no phasic activation following a fully predicted reward at the time
of outcome (i.e., the participant is fully aware to have pressed the button
in time and expects his/her reward). Hypothetically, this dopamine acti-
vation helps to explain functional activation elicited by conditioned
reward-indicating cues in the MID task. Figure modified and combined
according to Knutson et al. (2001b) and Schultz (1998)
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phase, the contrast images “gainminus neutral cues” and “loss
avoidance minus neutral cues” were computed combining the
three different values for gain and loss avoidance, respective-
ly. On the second-level, between-group differences were
assessed with separate full-factorial ANOVA designs for the
two abovementioned individual contrast images using an F-
contrast.
Given our strong a priori hypothesis for ventral striatal
activation during the anticipation phase of the MID task
(Knutson et al. 2001a, 2008), we used small-volume correc-
tion implemented in SPM 8 (significance level p<0.05,
family-wise error (FWE)-corrected). We also performed
whole-brain analyses with a threshold of p<0.05, FWE-
corrected. For post hoc t tests, we conducted five different
analyses in SPSS, comparing each diagnostic group to healthy
controls.
Correlations between fMRI signal and symptoms
of depression and anxiety
Self-ratings of depressed mood (BDI) had been applied in all
diagnostic groups except for patients with bipolar disorder
(acutemanic episode). Self-ratings of anxiety (STAI) had been
applied in all groups except for patients with schizophrenia. In
order to probe a relationship between VS activation and
depressed mood/anxiety, the following analyses were
performed:
We extracted the individuals’ mean parameter estimates
from the cluster that showed a significant activation in the
between-group F-contrasts “anticipation of gain minus neutral
cues” and “anticipation of loss minus neutral cues.” First, in
exploratory analyses, the mean parameter estimates were cor-
related with the subjects’ individual BDI and STAI scores
across diagnostic categories. These exploratory correlation
analyses were substantiated with partial correlation analyses
controlling for diagnostic category, age, gender, and smoking
behavior.
In a second step, we performed stepwise regression analy-
ses to test whether ventral striatal activation predicted de-
pressed mood or anxiety beyond the effects of diagnostic
category, age, gender, and smoking behavior.
Finally, to ensure that effects were not driven by significant
differences in the association between depressed
mood/anxiety and ventral striatal activation between diagnos-
tic categories, we computed an interaction term (specifically,
by multiplying the categorical variable “diagnostic category”
with the main predictor variable, ventral striatal activity) and
added this interaction term to the regression model. Here, a
significant effect for the interaction term would indicate a
significant difference in the association between ventral
striatal activity and depressed mood or anxiety between the
diagnostic categories.
Throughout the analyses, gender was coded as “1” for
males and “2” for females; smoking behavior was coded as
“1” for “smoker” and “2” for “non-smoker”; and the different
diagnostic categories were coded from “1” to “6” (1=healthy
controls, 2=patients with alcohol dependence, 3=patients
with schizophrenia, 4=patients with MDD, 5=patients with
bipolar disorder, acute manic episode, 6=patients with
ADHD). Due to the variety of substance classes, it was not
possible to convert the individuals’ medication in a meaning-
ful fashion; therefore, we added medication as a categorical
covariate, with “0” for “no medication and “1” for
“medication.”
Results
Behavioral data
Mean reaction times (RT) revealed a significant main effect of
cue type (F(2,174)=101.23, p<0.001), indicating faster re-
sponses during both gain and loss trials (RT gain>neutral, t=
−11.89, p<0.001; RT loss>neutral, t=−10.96, p<0.001; and
RT loss>RT gain, t=2.11, p=0.04). They also revealed a main
effect of group (F(5,174)=4.81, p<0.001), with patients having
a diagnosis of schizophrenia showing significantly slower
responses than patients with MDD, ADHD, and healthy con-
trols (post hoc t tests all p<0.007; for detailed results, please
see supplement Table 2). Please note that the MID task is
programmed to ensure equal percentages of gains and losses
by adjusting to individual reaction times (Beck et al. 2009;
Knutson et al. 2000). There was no group-by-cue interaction
(F(10,350)=0.85, p>0.5), and the reaction time patterns were
very similar in all participants, indicating that all participants
understood the paradigm and were engaged in the task.
Brain activation
When contrasting anticipation of gain versus a neutral condi-
tion, a significant effect of group was observed in the right VS
([x y z]=[12 15−9], F=4.59, p=0.008, FWE-corrected for
VS-ROI), and trendwise in left VS ([x y z]=[−15 9−6], F=
3.36, p=0.06, FWE-corrected for VS-ROI) (Fig. 2).
Post hoc t tests revealed a significant reduction in right VS
activation during reward compared to neutral anticipation in
patients with schizophrenia versus healthy controls (t=2.68,
p=0.009). This effect was independent of schizophrenia pa-
tients’ antipsychotic medication (please see Table 1): a two-
sample t test between medicated (n=28; mainly with first
generation antipsychotics) and unmedicated (n=16;
medication-free for at least four half-lives of the previously
given medication) patients revealed no significant differences
in right ventral striatal activation (t=−0.25, p=0.80). We also
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found a significant reduction in right VS activation in patients
with MDD compared to healthy controls (t=2.32, p=0.02)
and in patients with alcohol dependence compared to healthy
controls (t=2.46, p=0.03). There was no significant difference
in right ventral striatal activation between healthy controls and
patients with an acute manic episode (t=0.95, p=0.35) or
between healthy controls and patients with ADHD (t=−1.46,
p=0.15). Whole-brain analyses revealed no further group
differences outside the VS.
Correlations between fMRI signal and symptoms
of depression and anxiety
Anticipation of gain minus neutral cues
Participants with BDI did not differ significantly from partic-
ipants with missing BDI scores with regard to gender (F1=
0.15, p=0.7), age (F1=0.001, p=0.98), or smoking behavior
(F1=0.15, p=0.7). Patients with STAI did not differ signifi-
cantly from patients without STAI scores regarding age (F1=
3.7, p=0.06) and smoking behavior (F1=0.61, p=0.44); how-
ever, because STAI scores were not assessed in schizophrenia
patients (who included a substantial number of women), more
men than women had a STAI score (F1=7.25, p=0.008).
In our exploratory analyses, we observed a significant
negative bivariate correlation between right ventral striatal
activation (at [x y z]=[12 15−9]) and depressive symptoms
(Pearson’s r=−0.19, p=0.03), which was also found in the
partial correlation analyses controlling for age, gender,
smoking behavior, and diagnostic category (correlation coef-
ficient=−0.23, p=0.008).
To ensure that this effect was not driven by differences in
the direction or magnitude of the correlation between healthy
controls and patients, we split our sample accordingly and
repeated bivariate and partial correlation analyses. In bivariate
correlations, we found correlation coefficients of similar mag-
nitude and direction in both healthy controls (Pearson’s r=
−0.16) and patients (Pearson’s r=−0.15), which, however, did
not reach statistical significance (p=0.14 and p=0.09, respec-
tively). We observed the same effect in partial correlations
correcting for age, gender, smoking behavior, and diagnostic
category in healthy controls (correlation coefficient=−0.15,
p=0.33) and patients (correlation coefficient=−0.16, p=0.15).
These results suggest that the lack of significance is due to
decreased power and assert that no major difference in the
magnitude or direction of the correlation between patients and
controls generated the overall association.
In stepwise regression analysis, VS activations predict-
ed depressed mood beyond the effects of diagnostic cate-
gory, age, gender, and smoking behavior (beta=−0.20, p=
0.008). Since data on the BDI were skewed to the right
given the inclusion of healthy subjects (floor effect), we
log-transformed BDI sum score data. Again, results
showed that VS reward anticipation signal explained var-
iance above and beyond the effects of diagnostic category,
age, gender, and smoking behavior (beta=−0.21, p=0.01;
Fig. 3). This effect also remained significant when we
controlled for the effects of medication (beta=−0.21,
p<0.01). The application of the interaction term between
diagnostic category and VS activity did not yield signif-
icant results (beta=−0.19, p=0.31), indicating that differ-
ent diagnostic groups did not differ significantly in the
Fig. 2 Difference in VS BOLD response during reward compared to
neutral anticipation between diagnostic groups (see below). a Significant
main effect of group in right VS ([x y z]=[12 15−9], F=4.59, p=0.008,
FWE-corrected for VS-ROI; displayed at coronal section y=15, red
p<0.001, yellow: p<0.005; left upper insert sagittal section at x=12; right
insert glassbrain at p<0.001, k>2 showing the specificity of the finding). b
Plot of the mean parameter estimates of this cluster. HC, healthy controls
(n=54); AD, alcohol-dependent patients (n=26); Sz, schizophrenia patients
(n=44);MDD, major depressive disorder patients (n=24); Mania, bipolar
patients (acute manic episode; n=13); ADHD, attention deficit/hyperactiv-
ity disorder patients (n=23); a.u., arbitrary units
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association between the reward anticipation signal in the
right VS and depressive symptoms.
We found no significant correlation between right ventral
striatal activation (at [x y z]=[12 15−9]) and anxiety, mea-
sured with the STAI (Pearson’s r=0.03, p=0.78). Therefore,
no further analyses were applied.
“Anticipation of loss minus a neutral condition”
We did not observe a significant cluster of activation in the
between-group F-contrast “anticipation of loss minus neutral
cues.” Therefore, no further analyses were applied.
Discussion
To the best of our knowledge, this is the first study assessing
reward anticipation in adults across nosological boundaries in
a range of different psychiatric disorders. First, we observed a
significant reduction in right ventral striatal activation during
reward anticipation in patients with schizophrenia compared
to healthy controls. Ventral striatal hypoactivation was also
recently reported by Nielsen et al. (2012) and Esslinger et al.
(2012), who assessed reward anticipation in medication-free
patients with schizophrenia or schizoaffective disorder. In line
with this, reduced ventral striatal signaling was also observed
during reversal learning in unmedicated schizophrenia pa-
tients (Schlagenhauf et al. 2014). Our own sample consists
of unmedicated as well as medicated patients; however, post
hoc t tests revealed no significant differences between the two
subgroups. Our patients were mainly receiving first-
generation antipsychotics such as haloperidol or flupentixol;
this observation is in line with previous findings of our group
(Schlagenhauf et al. 2008), where we found ventral striatal
hypoactivation in schizophrenia patients receiving first-
generation antipsychotics, which normalized after a change
from first- to second-generation antipsychotics.
Secondly, we observed a reduction of right VS activation
during reward anticipation in patients with major depression
and in patients with alcohol dependence compared to healthy
controls. The moderate reduction in ventral striatal activation
in alcohol-dependent patients is in line with the more incon-
sistent literature on reward anticipation in alcohol dependence
(Bjork et al. 2012; Wrase et al. 2007). Unmedicated MDD
patients have also been reported to show nonsignificant or
rather moderate reductions in VS activation during reward
anticipation (Knutson et al. 2008; Pizzagalli et al. 2009;
Smoski et al. 2009; Stoy et al. 2012). Diagnostic group dif-
ferences in VS activation to reward-predicting cues can be due
to different degrees and patterns of dopamine dysfunction. For
example, in unmedicated schizophrenia, presynaptic dopa-
mine release is elevated (Abi-Dargham et al. 2009), while in
alcohol dependence, both dopamine release and D2 receptors
appear to be reduced (Heinz et al. 2005b; Martinez et al.
2005). In major depression, serotonin medication normalized
previously blunted VS activation during reward anticipation
(Stoy et al. 2012), pointing to an interaction between serotonin
and dopamine neurotransmitter systems in this affective
disorder.
Patients with acute manic episode or ADHD did not show
significant reductions in VS functional activation during re-
ward anticipation compared with healthy controls. Previous
studies reported mixed results regarding ventral striatal acti-
vation in ADHD, which was attributed to differences in psy-
chopathological symptom severity or medication status
(Carmona et al. 2012; Stoy et al. 2011).
No significant group differences were observed with re-
spect to loss anticipation. This finding is in line with previous
findings from our studies as well as others (Schlagenhauf et al.
2009; Stoy et al. 2011; Waltz et al. 2010). In cases where
group differences in ventral striatal activation during loss
anticipation between healthy controls and patients were found,
they tended to be small (Beck et al. 2009; Wrase et al. 2007).
This is in accordance with observations suggesting that in the
MID task, functional activation elicited by reward anticipation
(versus neutral cues) is stronger than activation elicited by loss
anticipation (versus neutral cues) (Heinz and Schlagenhauf
2010; Knutson et al. 2001a). The MID task thus appears to be
more suitable to assess ventral striatal correlates of gain
anticipation.
Critically, and in accordance with a dimensional approach
that cuts across nosological boundaries, we found a significant
Fig. 3 Correlation between fMRI signal and depressive symptoms dur-
ing reward anticipation. Significant negative correlation between right VS
reward anticipation signal at peak of group difference at [9 15−12] and
depression symptom severity (log-transformed BDI; beta=−0.21, p=
0.01). HC, healthy controls (n=49); AD, alcohol-dependent patients
(n=18); Sz, schizophrenia patients (n=29); MDD, major depressive dis-
order patients (n=21); ADHD, attention deficit/hyperactivity disorder
patients (n=15); LReg-Line, linear regression line across all subjects;
a.u., arbitrary units; log, log transformed.
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negative correlation between ventral striatal activation during
reward anticipation and severity of depressive symptoms in all
participants (with the sole exception of manic patients for
whom no BDI scores were available). We did not find a
correlation between anxiety symptom severity and neuronal
activity during reward anticipation. These observations show
that across nosological boundaries, depressive symptoms are
a direct correlate of dysfunction of reward anticipation in
several mental disorders, including schizophrenia. The BOLD
response observed in our study reflects the impact of afferent
inputs to the VS, which are in turn modulated by a multitude
of neurotransmitters, most prominently dopamine (Knutson
et al. 2004; Schlagenhauf et al. 2013; Schott et al. 2008). In
accordance with this hypothesis, phasic increases in dopami-
nergic neurotransmission during reward anticipation have
been associated with the attribution of motivational salience
to rewards and reward-indicating cues as well as the positive
mood that can accompany an expectation of reinforcement
(Drevets et al. 2001; Hasler et al. 2008). A dysfunction of
reward expectation can thus interfere with motivation and
positive effect elicited by reward-predictive cues and, in our
study, was directly correlated with the severity of depressive
symptoms. Indeed, apathy and anhedonia, clinical correlations
of (striatal) dopamine dysfunction (Gradin et al. 2011; Heinz
et al. 1994), are key symptoms of depression (according to
ICD-10 and DSM-IV). Anxiety, on the other hand, was not
directly correlated with dysfunction of reward anticipation.
Severity of anxiety has more often been associated with
alterations in serotonergic modulation of the amygdala and
other limbic areas (Hariri et al. 2002; Heinz et al. 2011). A
dimensional approach can target such mood states and their
hypothetically associated mechanisms (e.g., impaired antici-
pation and experience of reward and dopamine dysfunction)
across traditional disorders. Further studies will have to ex-
plore the association between anxiety, learning from punish-
ment, and serotonin dysfunction (Daw et al. 2002; Reimold
et al. 2008; Robinson et al. 2012).
Limitations
While all subjects were studied with the same scanner (1.5 T,
Magnetom VISION Siemens®) and paradigms, patient
groups—according to age differences in prevalence—were
not matched for age and smoking behavior, variables which
weremodeled as covariates in all analyses.We did not observe
significant gender differences; however, study conditions
were not designed to assess gender or age differences, and
further studies are required to explore such effects. Secondly,
we measured dimensional correlates of reward anticipation in
clinical disorders that we had previously assessed one by one,
comparing them with healthy controls. Therefore, we had
mainly acquired disorder-specific scores rather than applying
a larger psychological test battery for all participants, which is
a limitation of our study. In addition, other scales besides the
BDI can be applied to measure depressive symptoms in more
detail, as the BDI is a self-administered questionnaire with all
potential biasing due to self-reports (Bowling 2005). Finally,
the incorporation of further diagnostic groups known to in-
volve the dopaminergic system (e.g., obsessive-compulsive
disorder) would have been desirable; however, such data of
further groups were not at our disposal.
Altogether, our observations show that reward anticipation is
impaired in several psychiatric disorders, confirming the prom-
inent role of reward prediction and learning for complex human
behavior (Montague et al. 2004; O'Doherty et al. 2004; Schultz
2010; Tobler et al. 2007). Our study reveals differences between
diagnostic groups, in line with a categorical approach toward
psychiatric disorders. At the same time, our findings strengthen
the idea that psychiatric disorders are complex phenotypes
composed of patterns of symptoms (such as dysfunction of
anticipation and experience of reward versus punishment) and
suggest that symptoms with a comparable neurobiological sig-
nature (here, blunted VS activation) can be present in different
psychiatric disorders and contribute to negative mood across
nosological boundaries (Heinz 2002; Robbins et al. 2012; van
Os and Kapur 2009). Therefore, our findings can help to
explain why medication modulating, e.g., dopamine or seroto-
nin neurotransmission, has benefits in a variety of disorders.
The dimensional strategy, pursued, e.g., by the RDoC project
(Cuthbert 2014; Insel et al. 2010), suggests that neurobiological
research in psychiatric disorders can advance by targeting such
core mechanisms that are implicated in diverse clinical entities.
In the future, an integration of these approaches may help to
focus on therapeutic strategies to clinically relevant syndromes
within and across mental disorders.
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